COSMOS Pharmaceutical Receivables

The latest receivables for 3349.T is $20B as of May 2026. That compares with $12B in the prior-year period — up 64.7% year over year. Investors often review this figure alongside COSMOS Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, 3349.T's receivables moved from $12B to $20B — a 64.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in COSMOS Pharmaceutical's operating scale or balance-sheet position.

A receivables figure of $20B for 3349.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 3349.T's receivables ($20B), review year-over-year change from $12B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.